- Butantan-DV is a dengue vaccine made in Brazil.
- Anvisa approved it on 26 November.
- It is for people aged 12 to 59 years.
- The vaccine needs only one dose to work.
- One dose can help reach remote Amazon communities.
- Trials in Brazil had 16,000 volunteers over nearly a decade.
- The vaccine showed 74.7% overall and 91.6% severe efficacy.
- More than 1,000,000 doses are ready for distribution.
- It will join the national programme in early 2026.
Difficult words
- vaccine — medicine that helps the body avoid disease
- approved — to say yes to a new medicine
- dose — small amount of medicine for one timedoses
- remote — far away from towns and cities
- Trials — study to test a medicine or vaccine
- volunteers — person who joins a study by choice
- efficacy — how well a medicine or vaccine works
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you take a vaccine that needs one dose?
- Have you visited a remote area?
Related articles
Virtual diet and exercise program helps people with lymphoma
A study tested a virtual diet and exercise program for people getting chemotherapy for lymphoma. The program improved symptoms, attendance was high, and participants had better strength and physical performance during treatment.
Parents' Attitudes Linked to Binge Drinking and Greek Life
A study finds that parents who are more permissive about alcohol are linked to students joining fraternities or sororities and higher binge drinking during the first college year. Authors suggest parenting programs to reduce risk.
Air pollution linked to higher post-surgery risks in Utah
A study of 49,615 non-emergency surgeries on Utah’s Wasatch Front found that higher PM2.5 in the week before surgery was associated with more post-surgical complications. The research appears in Acta Anaesthesiologica Scandinavica.